Table 1.
Study outcomes of TARE for NET liver metastases.
| Lead Author, Year | n | Prospective? | Treatment Phase | ORR | SD | Symptom Response | Survival |
|---|---|---|---|---|---|---|---|
| Arslan, 2011 [17] | 10 | No | ? | 80% | 10% | NR | All alive at 4–28 mo |
| Cao, 2010 [15] | 51 | No | ? | 38% | 27% | NR | 36 mo |
| Saxena, 2010 [26] | 48 | No | ? | 55% | 23% | NR | 35 mo |
| Kalinowski, 2009 [19] | 9 | Yes | Refractory | 66% | 33% | Improved QoL | 57% alive at 36 mo |
| Kennedy, 2009 [27] | 148 | No | Refractory/salvage | 63.2% | 22.7% | NR | 70 mo |
| King, 2008 [22] | 34 | Yes | First-line* | 50% | 14.7% | 50% | 59% alive at 37 ± 2 mo |
| Murthy, 2008 [16] | 8 | No | Refractory/salvage | 12.5% | 50% | NR | 14 mo |
| Rhee, 2008 [23] | 20 22** |
Yes Yes |
Refractory Refractory |
50% 53.8% |
44% 38.5% |
NR NR |
28 mo 22 mo |
| Meranze, 2007 [24] | 10 | Yes | First-line | 40% | 60% | Improved QoL | 70% alive at 35 mo |
| McGrath, 2007 [25] | 26 | No | First-line/refractory | 58.3% | 33% | NR | 69% alive at 17.3 mo |
| Kennedy, 2006 [21] | 18 | No | First-line/refractory | 89% | NR | NR | 89% alive at 27 mo |
*combined with 5-FU.
**with Yttrium-90 glass microspheres, all others with Yttrium-90 resin microspheres. Median survival in last column unless otherwise indicated. ORR: objective response rate (complete + partial response). SD: stable disease. NR: not reported. QoL: quality of life.